The consensus views of an expert roundtable meeting are presented as updated management guidelines for using alemtuzumab in chronic lymphocytic leukemia. Since the publication of previous management guidelines in 2004 , clinical experience with alemtuzumab has grown significantly, especially regarding its efficacy and safety, management of cytomegalovirus (CMV) reactivation, identification of patient subgroups likely to benefit from alemtuzumab therapy and subcutaneous administration of alemtuzumab. The updated recommendations include (1) alemtuzumab monotherapy can be safely used as first-line therapy; (2) suitable patient subgroups for alemtuzumab therapy include elderly patients, patients with 17p deletion, patients with refractory autoimmune cytopenias and patients with profound pancytopenia at baseline due to heavily infiltrated bone marrow; (3) alemtuzumab treatment should be continued for 12 weeks (36 doses) whenever possible, and bone marrow examination may be considered at week 12 to evaluate response; (4) monitoring CMV reactivation by weekly PCR is mandated during therapy; when CMV reactivation becomes symptomatic or viremia increases, alemtuzumab therapy should be interrupted and anti-CMV therapy started; (5) subcutaneous administration is safe, easy to perform and appears equally effective compared with intravenous infusion and (6) our strong recommendation is that alemtuzumab combination therapy and consolidation therapy shall not be used outside carefully controlled clinical studies.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. In the United States, an estimated 15 110 new cases of CLL and 4390 deaths due to this disease are expected in 2008. 1 In Europe, more than 100 000 patients are believed to live with the disease. 2 Molecular heterogeneity is common in CLL. Cytogenetic analysis of 325 patients conducted at the time of CLL diagnosis found that 82% had chromosomal aberrations, the most frequent of which were deletions of 13q (55%), 11q (18%), and 17p (7%) and trisomy 12 (16%). 3 Specific cytogenetic features were strongly associated with disease course and survival; patients harboring 17p or 11q deletion had more rapidly progressing disease and shorter survival than patients with 13q deletion, trisomy 12 or normal cytogenetics. 3, 4 The poor prognosis of patients with 17p or 11q deletion is believed to be the result of abnormalities in the p53 pathway. The proportion of patients with p53 abnormalities (17p deletion or p53 overexpression/ mutation) tends to be higher in the relapsed/refractory population (50%, n ¼ 24) than in the previously untreated population (7%, n ¼ 88). 5 For younger patients with symptomatic disease, combination chemotherapy with fludarabine and cyclophosphamide (FC) is highly effective and has become the standard first-line treatment. 4, 6, 7 Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) achieved high response rates, 8, 9 and was recently shown to improve response rates and progression-free survival (PFS) significantly, compared with FC alone, in both previously untreated and relapsed/refractory CLL in large randomized trials. 10, 11 The alkylating agent chlorambucil is still widely used, especially in elderly patients for whom the goal of treatment is often cytoreduction and palliation. 12 Alemtuzumab (Campath and MabCampath; Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA and MabCampath; Bayer Schering Pharma, Berlin, Germany) is a recombinant humanized monoclonal antibody targeting the CD52 antigen. CD52 is a glycoprotein of unknown function that is highly expressed on cell surfaces of normal and malignant lymphocytes. 13 Binding of alemtuzumab to CD52 on lymphocytes induces complement-dependent cytotoxicity, 14, 15 antibody-dependent cell-mediated cytotoxicity 14 and direct cytotoxicity (likely apoptotic cell death), [16] [17] [18] although a direct cytotoxic effect of alemtuzumab was not observed in other studies and therefore remains controversial. 19, 20 Alemtuzumab received accelerated approval in the United States and Europe in 2001 for patients who had been treated with alkylating agents and in whom fludarabine therapy had failed. A recent randomized phase III trial (CAM307) compared alemtuzumab with chlorambucil as first-line treatment. 21 Based on the positive results of this study, alemtuzumab received full approval and an expanded indication in September 2007 in the United States and in January 2008 in Europe. 22 A previous version of management guidelines, based mainly on clinical experiences with alemtuzumab in patients with fludarabine-refractory CLL, was published in 2004. 23 Here, we present updated guidelines that incorporate recent clinical data and cumulative experience from more than 20 000 patients treated with alemtuzumab since its approval in 2001.
Alemtuzumab monotherapy for CLL
Alemtuzumab monotherapy in relapsed/refractory CLL has been reviewed previously. 23 We will focus on alemtuzumab monotherapy as first-line treatment for CLL. The first such study was a Swedish phase II study. Patients with symptomatic CLL received first-line s.c. alemtuzumab 3 times weekly (t.i.w.) for up to 18 weeks with the target dose of 30 mg. An overall response rate (ORR) of 87% (complete response (CR) 19%, partial response (PR) 68%) was achieved in 38 evaluable patients. 24 After a longterm follow-up, the median time to treatment failure (TTTF) was 28 months for all 38 evaluable patients, 32 months for the 33 responders and 77 months for the 7 patients who achieved CR. Compared with 75 carefully matched historical control patients who received alternative first-line treatment, patients treated with alemtuzumab achieved a higher ORR and CR rate, as well as longer TTTF. The incidence of infection was similar in patients receiving alemtuzumab and those receiving alternative treatment during both treatment and follow-up. 25 The efficacy and safety of first-line intravenous (i.v.) alemtuzumab were investigated by Hillmen et al. 21 in the randomized phase III CAM307 study. Treatment-naive patients (N ¼ 297) were randomized to receive i.v. alemtuzumab 30 mg t.i.w. for up to 12 weeks or oral chlorambucil 40 mg/m 2 every 28 days. Alemtuzumab therapy achieved significantly higher ORR, CR rates and longer PFS compared with chlorambucil (ORR 83 vs 55%, CR rate 24 vs 2%, PFS 14.6 vs 11.7 months), with a 42% reduction in the risk of disease progression or death (hazard ratio ¼ 0.58; P ¼ 0.0001). Alemtuzumab was also superior to chlorambucil with respect to time to alternative treatment and minimal residual disease (MRD) negativity. 21 Response rates for alemtuzumab compared favorably with those of single-agent rituximab (CR 9%, PR 49%). 26 Importantly, alemtuzumab was shown to be effective in patients with poor-risk cytogenetics (ORR 64% in patients with 17p deletion and 87% in patients with 11q deletion). 21 Patients in the CAM307 study were prospectively stratified by factors such as age and size of lymph nodes. Among patients with a maximum lymph node size Z 5 cm, an ORR of 76% and a median PFS of 11.1 months were achieved in the alemtuzumab arm, compared with an ORR of 44% and a PFS of 8.8 months in the chlorambucil arm. These findings were consistent with earlier results that showed an ORR of 86% in patients with lymph nodes 45 cm (compared with an ORR of 87% in patients with lymph nodes p5 cm). 24 It appears that patients with bulky lymphadenopathy (45 cm) may also benefit from first-line alemtuzumab therapy. It should be noted, though, that most responses to alemtuzumab in patients with bulky lymphadenopathy are PRs. 24 First-line alemtuzumab therapy was generally well tolerated. Incidences of grade 3 or 4 anemia and thrombocytopenia were similar between the alemtuzumab and chlorambucil arms ( Table 1) . 21 Although grade 3 or 4 neutropenia was more common with alemtuzumab (41 vs 25%), febrile neutropenia and sepsis were similarly rare in both arms. Cytomegalovirus (CMV) reactivation was the only drug-related serious adverse event more common with alemtuzumab than with chlorambucil. 21 Although the CAM307 study demonstrated significantly improved activity of alemtuzumab compared with chlorambucil, these data should be considered in perspective, because chlorambucil is no longer considered the standard of care for most patients with CLL. Recent randomized studies have established the role of FCR chemoimmunotherapy in both previously untreated and relapsed/refractory CLL, and it is likely that FCR will be adopted as the new standard of care for the majority of patients. However, there may be subgroups of patients who are unable to receive FCR or may not achieve good response to FCR and who therefore may benefit from alemtuzumab therapy in the first-line setting. Such patient subgroups are discussed further in the following section.
As with most new cancer therapeutics, alemtuzumab is relatively expensive. Our recommendations are based solely on clinical data without considering pharmacoeconomics.
Recommendations
In this section, we provide our recommendations regarding the use of alemtuzumab and patient management. The recommendations are also briefly summarized in Table 2 . Table 1 Safety results from CAM307 study: adverse events in X10% of patients
All grades, n (%) Grade 3 or 4, n (%) All grades, n (%) Grade 3 or 4, n (%) 
Treatment duration and response assessment
We recommend that alemtuzumab therapy be given for at least 12 weeks (36 doses) whenever possible, unless there are clear signs of progressive disease, and that bone marrow assessment be performed no earlier than week 12 (level of evidence: nonrandomized trials 24, 29, 30 ). Our recommendation is based on the rationale to maximize quality of response without causing undue toxicity. Our overall experience with alemtuzumab suggests that the length of therapy correlates with the quality of remission, which in turn correlates with patient outcomes. In patients receiving alemtuzumab therapy, although CR may be observed in the peripheral blood of almost all patients by week 4 (regardless of eventual bone marrow response), significant depletion of CLL cells in the bone marrow may not begin until circulating CLL cells have been completely eradicated from peripheral blood. 24, 30 Thus, longer treatment duration (such as 12 weeks or more) seems to be required to achieve maximal response in the bone marrow. 24, 29, 30 Whether therapy should be extended beyond 12 weeks remains uncertain, although some trials indicate that prolonged therapy may be beneficial (particularly with s.c. administration, which has slower pharmacokinetics). 24, 31 We recommend that such decisions should be made on an individual basis at the discretion of the treating physician. A recent survey indicates that in clinical practice, however, alemtuzumab therapy is often stopped at weeks 7-8, possibly based on 'cosmetic' response observed in the peripheral blood rather than in the bone marrow (personal communications with Bayer Schering Pharma). We want to emphasize the importance of maintaining a full course of 12-week therapy (unless there are signs of disease progression) and assessing response in the bone marrow.
Twelve-week alemtuzumab therapy generally has an acceptable safety profile in first-or later-line treatment. 21, 32 As discussed in previous guidelines, toxicity with single-agent alemtuzumab therapy typically occurs early and on a relatively predictable schedule, allowing for implementation of appropriate prophylaxis and management strategies. Moreover, the incidence of adverse events decreases over time, and CMV events are rare after week 8. 23 As polymerase chain reaction (PCR)-based CMV monitoring becomes common practice, CMV reactivation can be detected early and managed effectively. Late-occurring infections are possible, particularly in relapse/ refractory patients. The management of CMV events and non-CMV infectious complications will be discussed below in further detail.
Dose recommendations and administration routes
The approved dosing schedule of alemtuzumab is 30 mg through i.v. infusion over 2 h (not i.v. push or bolus) t.i.w. for 12 weeks, after dose escalation from 3 to 10 to 30 mg daily or as tolerated. This regimen has been used in the majority of clinical trials. The alemtuzumab prescribing information cautions that single doses higher than 30 mg and weekly cumulative doses higher than 90 mg may increase the incidence of pancytopenia. 27 A small study indicated that a lower dose (10 mg) of alemtuzumab may also be effective, 33 but in the absence of further studies, a lower dose is not recommended at present. We recommend that less-frequent dosing (once or twice per week) be avoided, because unpublished observation from early trials in the 1990 s indicated that t.i.w. dosing of single-agent alemtuzumab may be superior to less-frequent dosing with respect to clinical effectiveness (level of evidence: empirical). The alemtuzumab prescribing information can be referred to for recommended dose modifications for neutropenia and thrombocytopenia; no modification is recommended for lymphopenia. 27 Subcutaneous administration has emerged as a feasible and effective delivery route for alemtuzumab. In the study by Lundin et al., 24 41 previously untreated CLL patients received s.c. alemtuzumab at a dose of 30 mg t.i.w. for up to 18 weeks after s.c. dose escalation. Transient first-dose skin reactions occurred with s.c. administration, prolonging duration of the doseescalation phase to 2 weeks in some cases; other first-dose reactions were rare or absent with the exception of low-degree fever. The response rates and duration of response were similar to those seen with first-line i.v. alemtuzumab. 21, 24 In a phase II trial in patients with fludarabine-refractory CLL (CLL2H trial of the German CLL Study Group), s.c. alemtuzumab was given at 
Patient management
Hematologic events Refer to alemtuzumab prescribing information for treatment interruption and dose modification. 27 Use supportive therapy (G-CSF or irradiated blood product) when indicated Infections
Cotrimoxazole prophylaxis for P. jirovecii pneumonia and aciclovir prophylaxis for herpes virus CMV reactivation Clinical watch and weekly CMV test Refer to O'Brien et al. 28 for treatment of CMV reactivation Infusion-related events Antihistamine and acetaminophen premedication Corticosteroid prophylaxis is recommended, but at week 1 only Injection-site skin reactions Antihistamine and acetaminophen premedication Corticosteroid prophylaxis is recommended, but at week 1 only Abbreviations: CMV, cytomegalovirus; G-CSF, granulocyte colony-stimulating factor; s.c., subcutaneous; t.i.w., three times per week.
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The ORR was 32% (CR 4%, PR 28%), median PFS was 7.7 months and median OS was 19.1 months. 34 Again, in patients with refractory CLL, s.c. alemtuzumab showed similar efficacy, compared with i.v. alemtuzumab. 32 First-dose skin reactions are less prominent in previously treated patients than in those who received s.c. alemtuzumab as first-line treatment, and delay of the second or third s.c. dose is not needed for previously treated patients. 24 It may also be possible to skip alemtuzumab dose escalation; an up-front 30 mg dose resulted in acceptable side effects without a delay in administration of the second dose. 35, 36 The s.c. route is also attractive because of the feasibility of self-administration. In the study by Lundin et al., most patients were able to self-administer treatment after completion of the dose-escalation phase and disappearance of skin reactions. 24 Subsequent studies also demonstrated the feasibility of selfadministration of s.c. alemtuzumab. 37, 38 The s.c. self-administration strategy has been successfully applied in routine practice at many experienced centers, offering maximal convenience and cost-saving, because a 36-visit schedule of 2 h infusions required for i.v. alemtuzumab may be costly and difficult for many patients to accommodate.
In light of these data on s.c. alemtuzumab, we recommend that s.c. administration may be used instead of i.v. administration. The recommended dosage of s.c. alemtuzumab is the same as that of i.v. alemtuzumab (30 mg t.i.w. for 36 doses over 12 weeks). Regimens other than 30 mg t.i.w. are not recommended. Dose escalation may be prolonged to up to 2 weeks in the event of symptomatic local skin reactions (level of evidence: nonrandomized trials 24, 34 ). and/or targeted agents have not experienced similar safety concerns. 39, 40, 43, 45 Our strong recommendation is that alemtuzumab-containing combination therapy shall not be used outside carefully controlled clinical studies (level of evidence: unpublished randomized controlled trial).
Combination therapy and maintenance therapy in CLL
Alemtuzumab has also been explored as consolidation therapy or as maintenance therapy. Encouraging activities of alemtuzumab consolidation were observed, including improvement in quality of response, 47, 48 MRD eradication [49] [50] [51] and prolonged PFS. 52 However, safety concerns (particularly infectious toxicity) were raised in academic-center-based trials 51, 53 and in a community-based trial. 54 Other reported studies of alemtuzumab consolidation therapy have not experienced similar safety problems. [47] [48] [49] [50] We strongly recommend that alemtuzumab should not be used outside carefully controlled clinical trials as consolidation or maintenance therapy following any type of induction therapy (level of evidence: randomized controlled and nonrandomized trials 51, 53, 54 ). The causes for increased toxicity in some trials discussed above are not clear and may be related to patient characteristics, dose/schedule of alemtuzumab and combination partners, management strategies, 'rest period' between induction chemotherapy and alemtuzumab consolidation, and/or other factors. It may be speculated that rapid elimination of CD52 þ leukemic cells by combination therapy results in a low disease burden; similarly, in the consolidation setting, patients have a low initial disease burden because of prior induction therapy. As a consequence, the exposure of normal CD52 þ cells to alemtuzumab increases, leading to excessive depletion of immune cells and infectious toxicity. Further investigations are needed to better define the role of alemtuzumab combination therapy and consolidation therapy, which remain an active area of clinical investigation.
Suitable patient populations for alemtuzumab
As discussed earlier, there are subgroups of patients who may benefit from first-line alemtuzumab therapy. We will discuss these patient subgroups in detail.
Elderly patients. First-line alemtuzumab therapy is effective and safe in elderly patients. 21, 24 In CAM307 study, ORR among 53 patients X65 years of age who received alemtuzumab was 76%, compared with 56% among 52 patients X65 years of age who received chlorambucil (P ¼ 0.0409), whereas PFS was not significantly different between the two groups. 21 Similarly, high ORR was observed in elderly patients receiving first-line s.c. alemtuzumab, 24 probably due to good tolerability and few early dropouts.
Toxicity is an important factor to consider when formulating treatment plans for elderly patients. Although fludarabine induces high response rates, it is sometimes not well tolerated by elderly patients. Moreover, no survival benefits were demonstrated for fludarabine over chlorambucil in first-line treatment of elderly patients in the German CLL5 study. 55 On the other hand, alemtuzumab induces a high response rate in elderly patients without causing unacceptable toxicities. We conclude that alemtuzumab is a useful treatment option for elderly patients if the goal of treatment is disease remission or if the patient has aggressive disease (level of evidence: randomized controlled trial 21 ). More generally, younger patients (o65 years) who have impaired renal function (and who are therefore less tolerant of fludarabine) may also be good candidates to receive alemtuzumab therapy.
Patients with 17p deletion. The presence of 17p deletion and/or p53 mutations is predictive of the worst prognosis in CLL, characterized by rapid disease progression and shortest survival. 3 These outcomes are thought to be related to the loss of functional tumor suppressor p53. Accumulating data have demonstrated that response to alemtuzumab is independent of the status of 17p deletion or p53 mutations. The first evidence came from a case report of a patient with fludarabine-refractory, 17p-deleted CLL who achieved MRD-negative CR following alemtuzumab therapy. 56 In the CLL2H study of s.c. alemtuzumab in fludarabine-refractory patients, the ORR was 54% among 13 patients with 17p deletion. 34 In another study of s.c. alemtuzumab in patients with fludarabine-refractory disease, the ORR in 15 patients with p53 mutations or 17p deletion was 40%. 57 A database review of previously treated patients who received alemtuzumab i.v. or s.c. found that ORR did not differ significantly between patients with p53 deletions (50%) and patients without p53 deletions (55%). 58 In the CAM307 study, 11 patients in the alemtuzumab group and 10 patients in the chlorambucil group had 17p deletion. Among those patients, ORR and median PFS appear superior in the alemtuzumab arm (64% and 10.7 months, respectively) compared with the chlorambucil arm (20% and 2.2 months, respectively), although the differences did not reach a significant level. 21 Finally, a recent phase II trial investigated the efficacy of first-line low-dose (10 mg t.i.w.) s.c. alemtuzumab therapy in patients with 17p deletion. Of 48 patients enrolled, CR was observed in 7% of patients and PR in 33% of patients. Two patients achieved MRD negativity as assessed by four-color flow cytometry. 59 It should be noted that although alemtuzumab is an effective therapy for patients with 17p deletion, these patients still have a poor prognosis. Among the patients who received alemtuzumab in the CAM307 study, those with 17p deletion had a median PFS of only 10.7 months, compared with those with normal cytogenetics (19.9 months), trisomy 12 (18.3 months) or sole 13q deletion (24.4 months). 21 Nevertheless, because no other alternative therapy has proven equally effective or superior to alemtuzumab in the 17p deletion subpopulation, we believe that alemtuzumab remains a reasonable first-and later-line treatment option for these patients. We conclude that alemtuzumab is an effective treatment for patients with 17p deletion and that following alemtuzumab therapy, the option of allogeneic stem cell transplantation may be explored without delay, especially for younger patients (aged o65 years) (level of evidence: randomized controlled and nonrandomized trials 21, 34, [56] [57] [58] ).
Patients with pancytopenia. Neutropenia, thrombocytopenia and transfusion dependence resulting from heavily infiltrated bone marrow and/or previous therapy make it problematic for patients with pancytopenia to receive stem-cell-toxic chemotherapy regimens, whereas alemtuzumab may clear the bone marrow with no major hematologic toxicity. Alemtuzumab therapy in this setting may even allow subsequent myelosuppressive therapy when blood counts have increased. For the small subset of patients who present with pancytopenia at baseline due to heavily infiltrated bone marrow, alemtuzumab may be considered an option for first-line therapy (level of evidence: empirical).
Patients with autoimmune hemolytic anemia and autoimmune thrombocytopenia. Autoimmune disorders are frequent in CLL, and autoimmune hemolytic anemia (AIHA), the most common one, is associated with more advanced disease. 60 Case reports and small case series have described the efficacy of alemtuzumab in treating refractory, life-threatening AIHA and autoimmune thrombocytopenia in patients with CLL. In five patients with advanced CLL and severe, transfusiondependent, therapy-resistant AIHA, treatment with s.c. or i.v. alemtuzumab 30 mg t.i.w. for up to 12 weeks produced an increase of at least 2 g per 100 ml in hemoglobin concentration and eliminated the requirement for transfusion in 4-7 weeks. 61 A schedule of low-dose s.c. alemtuzumab (10 mg t.i.w. for 10 weeks) in heavily pretreated patients with CLL and transfusiondependent AIHA achieved an increase of at least 2 g per 100 ml in hemoglobin concentration and independence from transfusions in 5-8 weeks. 62 Although alemtuzumab itself may cause AIHA, according to the product label, we maintain our recommendation that alemtuzumab may be given to patients with AIHA or autoimmune thrombocytopenia who do not respond to conventional therapy. Alemtuzumab may also be considered one of several options for patients who present up front with active autoimmunity when anti-CLL therapy is also needed (level of evidence: case reports and small case series 61, 62 ).
Patient management
The 2004 guidelines provided detailed recommendations for prophylaxis and patient management. 23 Here, we provide a brief review and update of this information.
Hematologic events. Transient and reversible cytopenias are common with alemtuzumab treatment. Platelet nadirs occur mostly during weeks 2-4; neutrophil nadirs are typically observed between weeks 4 and 6. Both neutropenia and thrombocytopenia events are manageable, and adequate recovery can usually be achieved by weeks 6 -8. The alemtuzumab prescribing information summarizes recommendations for treatment interruption and dose modification in the event of neutropenia and thrombocytopenia. We recommend that alemtuzumab therapy should be stopped temporarily in the case of hemorrhage or febrile neutropenia (level of evidence: empirical). Past guidelines state that clinical judgment should be exercised when incorporating granulocyte colony-stimulating factor (G-CSF) as supportive therapy in the event of absolute neutrophil count o500 per ml. 23, 63 We maintain the recommendations of the 2004 guidelines on the use of G-CSF to avoid unnecessary delay and temporary stop of alemtuzumab therapy. We also recommend the use of irradiated blood product when supportive transfusion therapy is required (level of evidence: empirical). Because of the potential for transfusion-associated graft-vs-host disease in severely lymphopenic patients, blood products should be irradiated before use.
Infections. Compromised immune function combined with the immunosuppressive nature of alemtuzumab makes patients with CLL susceptible to a variety of infections during and for some period after treatment. One recent study revealed the temporal alignment of T-cell and neutrophil nadirs with the timing of appearance of CMV reactivation, pulmonary infection and all other infections (Figure 1) , demonstrating that the median time of infection onset occurred after the median time of immune cell nadir. 64 The incidence of infection appears to be lower in first-line alemtuzumab therapy than in second-line or later therapy. 21, 32 Recommendations for management of non-CMV infections remain unchanged from the 2004 guidelines. 23 We maintain the recommendation that cotrimoxazole (or pentamidine inhalation, for cotrimoxazole-allergic patients)
prophylaxis be continued for at least 6 months following cessation of alemtuzumab therapy to minimize the risk of late-occurring Pneumocystis jirovecii pneumonia. We also keep the recommendation that all patients must receive acyclovir prophylaxis for 6 months after cessation of alemtuzumab therapy to minimize the risk of severe herpes virus reactivation (level of evidence: empirical).
CMV reactivation. Cytomegalovirus reactivation is a wellknown complication of alemtuzumab treatment. O'Brien et al. 28 estimated the incidence of CMV reactivation to be 4-29%, using data from seven clinical trials of single-agent alemtuzumab. In the first-line CAM307 study, 16% of alemtuzumab-treated patients had PCR-positive, symptomatic CMV reactivation, and 52% had PCR-positive, asymptomatic CMV reactivation. All symptomatic patients successfully recovered following treatment interruption and anti-CMV therapy. 21 We recommend mandatory weekly monitoring for CMV reactivation by quantitative PCR during alemtuzumab therapy. Nevertheless, laboratory monitoring should never replace careful clinical watch for early signs of CMV reactivation, such as low-degree fever, fatigue and rising C-reactive protein. In such cases, CMV PCR analysis must be conducted without delay. A single positive CMV test in an otherwise asymptomatic patient does not necessarily mandate treatment interruption. However, alemtuzumab therapy should be held in the event of an increasing copy number of CMV in blood or symptomatic CMV reactivation. Alemtuzumab may be restarted in most cases following successful anti-CMV therapy, cessation of any symptoms and sustained negative CMV PCR (level of evidence: empirical).
We also emphasize that patients with fever and a negative CMV PCR analysis must be checked for other pathogens; the most important actions include computed tomography scan of the lungs (if needed, bronchoscopy þ bronchoalveolar lavage) for Pneumocystis diagnosis and blood cultures and PCR for diagnosis of adenovirus, Epstein-Barr virus and other potential viral pathogens (level of evidence: empirical).
The recently published CMV management guidelines can be referred to for details of CMV management in patients receiving alemtuzumab therapy. 28 One suggested strategy to manage CMV reactivation is to use up-front oral valganciclovir prophylaxis, which has been shown to be effective in preventing CMV events in patients receiving alemtuzumab-based therapy. 65 In this study, however, 27% of patients had disease other than CLL, and only 12.5% of patients received alemtuzumab monotherapy (majority of patients received alemtuzumab combination therapy). Therefore, it remains uncertain whether such prophylactic strategy should be adopted in routine clinical practice. We think that valganciclovir prophylaxis may be used at the discretion of the treating physician in patients at elevated risk for CMV reactivation and that if it is used, patients should be monitored carefully because of the risks of myelosuppression.
Infusion-related events. Infusion-related adverse events are generally grade 1 or 2 and occur most commonly during the first week of therapy. Recommendations for the management of infusion-related events remain unchanged from the 2004 guidelines. 23 Briefly, oral premedication with antihistamine and acetaminophen are given before infusion. Corticosteroids (oral or i.v.) may also be used (at weeks 1-2). To manage rigors, infusion should be halted and i.v. pethidine be administered. Antiemetic agents are recommended for pethidine-associated nausea. In the event of skin rash, additional oral antihistamine every 4 h is indicated, and oral hydrocortisone may be given in severe cases. For patients who have experienced severe infusion-related events, i.v. hydrocortisone premedication should be added to subsequent infusions. If corticosteroids are used, they should be tapered off as soon as possible (within 1-2 weeks).
Injection-site skin reactions. Subcutaneous administration of alemtuzumab is associated with injection-site skin reactions, including skin erythema and edema. Prophylaxis against firstdose skin reactions following s.c. administration is identical to that recommended for i.v. use.
Repeat treatment and follow-up
Retreatment with alemtuzumab in responders has been assessed in a small number of patients and has demonstrated promising results. A recent analysis of 17 patients demonstrates that alemtuzumab retreatment in former responders can achieve PR and stable disease in 53 and 18% of patients, respectively. Overall survival was positively associated with the length of the interval between the last dose of the initial course of alemtuzumab and start of retreatment. Median overall survival was 8.4 months among patients who required retreatment within 10.3 months of the last dose of the initial course, whereas median overall survival was not yet reached among patients who were retreated after a longer interval. 66 Guidelines for retreatment are not well developed at present. Our 2004 recommendations were based largely on case reports and personal communications, with dosing schedules individualized to the patient. 23 The National Comprehensive Cancer Network's Clinical Practice Guidelines in Oncology for NonHodgkin's Lymphoma, v.2.2009, state that treatment options for patients with relapsed CLL are similar to those for patients receiving initial therapy and that considerations in the choice of treatment are the duration of remission and the agent(s) used for initial therapy. 67 Specific information regarding retreatment of relapsed patients with the same agent used for initial therapy is not included. More data are needed before specific guidelines regarding alemtuzumab retreatment can be formulated. 
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Conclusions and overall recommendations
After extensive discussion, we have agreed on the following recommendations: (1) alemtuzumab monotherapy can be safely used as first-line therapy; (2) suitable patient subgroups for firstand later-line alemtuzumab therapy include elderly patients, patients with 17p deletion, patients with pancytopenia due to heavily infiltrated bone marrow and patients with refractory autoimmune cytopenia; (3) alemtuzumab treatment should be continued for at least 12 weeks, whenever possible, and bone marrow assessment should be considered at week 12 to determine treatment response; (4) patients should be monitored weekly for CMV reactivation during therapy, and therapy should be held in the event of symptomatic CMV reactivation; (5) s.c. administration is safe, simplifies treatment for patients and health care providers, and appears equally efficacious compared with i.v. administration and (6) our strong recommendation is that alemtuzumab-containing combination therapy and alemtuzumab maintenance therapy shall not be used outside carefully controlled clinical studies.
Conflict of interest
All authors received an honorarium from Bayer Schering Pharma for participating in an advisory board meeting in Madrid, Spain on 3 November 2007 that served as a starting point for the guidelines discussion. The authors did not receive an honorarium for preparing the guidelines nor for writing the paper. AÖ , RFB, CG and CMW have received research grants from Bayer Schering Pharma.
